Research programme: TriMix MEL - eTheRNA immunotherapeutics
Alternative Names: ECI-001; ECI-003; ECI-007; TriMix immunotherapies; TriMix immunotherapies - eTheRNA immunotherapiesLatest Information Update: 28 Dec 2021
At a glance
- Originator eTheRNA Immunotherapies
- Developer eTheRNA Immunotherapies; Vrije Universiteit Brussel
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Dendritic cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Hepatitis B; HIV infections; Human papillomavirus infections; Liver cancer
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Breast-cancer(Early-stage disease, First-line therapy) in Belgium (Intratumoural, Injection)
- 28 Aug 2021 No recent reports of development identified for preclinical development in Hepatitis-B in Belgium (Injection)
- 28 Aug 2021 No recent reports of development identified for preclinical development in Human-papillomavirus-infections in Belgium (Injection)